News

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide “Vaccinations & Therapeutic Drugs for COVID-19“, containing…

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…

In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…

Alla luce dei rapidi sviluppi scientifici nel campo della talassemia e dell’anemia falciforme con nuovi farmaci e trattamenti che promettono di rivoluzionare la gestione di queste malattie, la Federazione Internazionale…